The seventh annual BIO-Europe Spring® international partnering
conference will be held at the CCIB Convention Centre Barcelona in
Barcelona, Spain, March 11-13, 2013. High attendance by pharma and
biotech investors and venture capital firms is expected at the event,
which will draw more than 2,000 executive-level attendees from over
"Over recent years, the role of VCs has really changed," said Carola
Schropp, President of EBD Group. "At BIO-Europe Spring, many of the
funds that still invest early will be present. There will be several
workshops where investors will sit down with pharma to discuss
collaborative approaches to financing early stage biotechs. This goes to
show that both pharma and venture have taken on new roles in driving
One highlight of the program is the Monday morning, March 11, workshop
entitled "Exploring alternative financing models," moderated by Steve
Dickman, CEO of CBT Advisors, and featuring panelists from VC firms
including Sinclair Dunlop, Managing Partner of Rock Spring
Ventures; Joël Jean-Mairet, General Partner of Ysios Capital; Kevin
Johnson, Partner of Index Ventures; as well as Melissa Stevens,
Deputy Executive Director of FasterCures.
The workshop will highlight issues related to the shortage of
traditional VC investments and the growing prevalence of creative
financing models for early stage and pre-IPO start-ups. The workshop is
expected to foster an engaging discussion on these new investment
approaches and what is driving this trend in the market.
"These days there is a lot of interest in early stage investing," said Joël
Jean-Mairet, Managing Partner at Ysios Capital, a Barcelona-based
firm. "Investors are eager to tap into new drug development candidates
earlier on provided that these are highly disruptive, and there are a
lot of creative financing models developing in the field to capitalize
on this early innovation while keeping the investments lucrative. I
think the panel at BIO-Europe Spring will be extremely informative to
both investors and biotech."
"There is a significant amount of untapped discovery out there, and many
high potential young companies require capital to achieve critical
milestones in the discovery process," said Sinclair Dunlop of
Rock Spring Ventures. "Current investment models are failing to deploy
sufficient early stage capital to these types of high growth companies."
Sander Slootweg, Managing Partner of Forbion Capital Partners,
will moderate a panel called "Going public: A review of 2012's IPOs"
with panelists Barbara Duncan, CFO of Intercept Pharmaceuticals; Dan
Dubin, Managing Director and Vice Chairman of Leerink Swann; C.A.
(Oscar) Izeboud, Managing Director of Kempen & Co Corporate Finance
B.V.; and Daniel Paterson, VP and Head, Corporate Development and
Diagnostics of Verastem.
"One main topic we are going to explore on the panel is the differences
between the EU and the US markets for IPOs and, more broadly, the
capital markets and how we can potentially improve the functioning of
the capital markets in Europe. This is certainly of interest to
potential investors, and is part and parcel of what BIO-Europe Spring is
about," said Slootweg.
"The choices we make need to be the right ones for years to come.
Addressing real medical needs is what drives our strategy and brings us
with a higher probability to the right programs. Then it requires
quality analysis to identify the best people and the best science.
BIO-Europe Spring is an excellent place to get in touch with potential
right partners," said Olivier Litzka with Edmond de Rothschild
Investment Partners. Since 2005, Rothschild has supported 25 European
biotech and medtech companies, and, while now at EUR 170 million raised,
is planning the closing of its EUR 200 million BioDiscovery4 fund in
late spring. Litzka is on a panel called Therapeutic Insight:
The Host Committee for BIO-Europe Spring 2013 in Barcelona is
coordinated by Biocat
and the Barcelona
City Council-through Barcelona Activa-and receives support from
other sector organizations and companies from the BioRegion of
Catalonia, including Almirall, Amgen, Biokit, Reig Jofré and Ysios
The 2012 edition was held in Amsterdam, The Netherlands, and welcomed
2,157 delegates representing 1,304 companies vying for an estimated
2,508 licensing opportunities. 11,172 one-to-one meetings took place at
that event among companies across the life science value chain, from
large biotech and pharma companies to financiers and innovative
One-to-one partnering meetings for the 2013 edition in Barcelona can be
requested utilizing partneringONE®. To be included in the first round of
scheduling, request your meetings by March 1.
As the leading conference networking solution for the life sciences, the
system generates over 40,000 one-to-one meetings annually at EBD Group's
six life science partnering events held around the world. With
partneringONE, pharma and biotech dealmakers can create a partnering
profile and begin efficiently identifying and requesting meetings with
potential collaborators. For more about partneringONE and how to log on
to your account, go to www.ebdgroup.com/bes/partnering/index.php.
Information for BIO-Europe Spring can be found online at http://www.ebdgroup.com/bes.
Follow EBD Group on Twitter: twitter.com/ebdgroup
Notes to Editors:
Entry to BIO-Europe Spring 2013 is free to members of the press,
including full access to the partnering system, sessions, press
conferences, workshops, and pre-arranged partnering meetings. Visit the
BIO-Europe Spring conference website at http://www.ebdgroup.com/bes/press_reg.htm
for registration details.
About EBD Group
EBD Group is the leading partnering firm for the global life science
industry. Since 1993, biotech, pharma and medical device companies have
leveraged EBD Group's partnering conferences, technology and services to
identify business opportunities and develop strategic relationships
essential to their success.
EBD Group's conferences are run with the support of leading corporations
and international trade associations and include:
EBD Group's sophisticated web-based partnering service, partneringONE®,
is also used as the partnering engine at numerous third-party events
around the world, and partnering360® is the
open online community of life science dealmakers that enhances
partnering experiences all year long.
Outside of the conference format, EBD Group's consultants provide
hands-on assistance for firms seeking to in- or out-license products and
EBD Group has offices in the USA and Europe.
For more information please visit www.ebdgroup.com.
Photos/Multimedia Gallery Available: http://www.businesswire.com/multimedia/home/20130219007266/en/
[ Back To NFVZone's Homepage ]